{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:36:13Z","timestamp":1789662973621,"version":"4.0.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["ATVB"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>\n                    Blood pressure management involves antihypertensive therapies blocking the renin-angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the so-called RAS escape phenomenon, elicited by the compensatory renin elevation upon RAS blockade. Recently, evidence points toward targeting hepatic AGT (angiotensinogen) as a novel approach to block the RAS pathway that could circumvent the RAS escape phenomenon. Removing AGT, from which all angiotensins originate, should prevent further angiotensin generation, even when renin rises. Furthermore, by making use of a trivalent\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    -acetylgalactosamine ligand\u2013conjugated small interfering RNA that specifically targets the degradation of hepatocyte-produced mRNAs in a highly potent and specific manner, it may be possible in the future to manage hypertension with therapy that is administered 1 to 2\u00d7 per year, thereby supporting medication adherence. This review summarizes all current findings on AGT small interfering RNA in preclinical models, making a comparison versus classical RAS blockade with either ACE (angiotensin-converting enzyme) inhibitors or AT1 (angiotensin II type 1) receptor antagonists and AGT suppression with antisense oligonucleotides. It ends with discussing the first-in-human study with AGT small interfering RNA.\n                  <\/jats:p>","DOI":"10.1161\/atvbaha.123.319897","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T05:00:58Z","timestamp":1697691658000},"page":"2256-2264","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Targeting Angiotensinogen With\n                    <i>N<\/i>\n                    -Acetylgalactosamine\u2013Conjugated Small Interfering RNA to Reduce Blood Pressure"],"prefix":"10.1161","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-5032","authenticated-orcid":true,"given":"Dien","family":"Ye","sequence":"first","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands (D.Y., E.O.C.-L., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-5720","authenticated-orcid":true,"given":"Edwyn O.","family":"Cruz-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands (D.Y., E.O.C.-L., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8904-8239","authenticated-orcid":true,"given":"Ho-Chou","family":"Tu","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (H.-C.T., I.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-3032","authenticated-orcid":true,"given":"Ivan","family":"Zlatev","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA (H.-C.T., I.Z.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-3585","authenticated-orcid":true,"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands (D.Y., E.O.C.-L., A.H.J.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01225-8"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08729"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199002000-00015"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.23.4.439"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02893"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09755"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.12703"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20201239"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026426"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16876"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.04.004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00238309"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.123802"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.67.3.564"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15955"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00323.2011"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06040"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.316590"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.29.6.1240"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12352"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja505986a"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.021"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913147"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.05.012"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.019"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz140"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa077"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa670"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac539"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02989-4"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku531"},{"key":"e_1_3_3_37_2","first-page":"273","volume-title":"Pharmacological properties of 2\u2019-O-methoxyethyl-modified oligonucleotidesAntisense Drug Technology: Principles, Strategies and Applications","author":"Bennett CF","year":"2007","unstructured":"Bennett, CF. Pharmacological properties of 2\u2019-O-methoxyethyl-modified oligonucleotides. In: Crooke, ST, ed. Antisense Drug Technology: Principles, Strategies and Applications. CRC Press: 2007; 273\u2013304."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx060"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0753"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c01755"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02041"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08922"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0937-8"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.1.73"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.30.1.42"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.96.1.220"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp012"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000236"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)31697-1"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.453"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011121159"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001027"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316672348"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.14845"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-020-01037-1"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.12873"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.07012"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311817"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.318075"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154337"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.18731"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021712"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05267"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.111118"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99417"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318792537"}],"container-title":["Arteriosclerosis, Thrombosis, and Vascular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/ATVBAHA.123.319897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T14:40:37Z","timestamp":1748529637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.123.319897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1161\/ATVBAHA.123.319897"],"URL":"https:\/\/doi.org\/10.1161\/atvbaha.123.319897","relation":{},"ISSN":["1079-5642","1524-4636"],"issn-type":[{"value":"1079-5642","type":"print"},{"value":"1524-4636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}